Literature DB >> 22989837

HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica.

Shoko Deguchi1, Kentaro Deguchi, Kota Sato, Taijun Yunoki, Yoshio Omote, Nobutoshi Morimoto, Tomoko Kurata, Masami Ikeda, Toshiyuki Takahashi, Masashi Aoki, Koji Abe.   

Abstract

We herein report the case of a 60-year-old man showing overexpression of creatine kinase (hyperCKemia) related to initial and recurrent attacks of neuromyelitis optica (NMO). He showed reduced vision, ataxia and dysesthesia, but no symptoms originating in the muscles. Magnetic resonance imaging (MRI) revealed lesions in the optic nerve, medulla oblongata, and spinal cord similar to typical NMO patients. However, femoral MRI and whole positron emission tomography (PET) demonstrated no abnormal findings during an episode of hyperCKemia. This case suggests that hyperCKemia is partly involved in the pathogenesis of NMO in both the central nervous system and myofiber surface, which is usually difficult to detect by clinical imaging modalities alone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989837     DOI: 10.2169/internalmedicine.51.7898

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  14 in total

Review 1.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

2.  Transient hyperckemia in the setting of neuromyelitis optica (NMO).

Authors:  Rabia Malik; Aaron Lewis; Bruce A C Cree; Julien Ratelade; Andrea Rossi; Alan S Verkman; Andrew W Bollen; Jeffrey W Ralph
Journal:  Muscle Nerve       Date:  2014-09-24       Impact factor: 3.217

Review 3.  Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.

Authors:  Sean J Pittock; Claudia F Lucchinetti
Journal:  Ann N Y Acad Sci       Date:  2015-06-10       Impact factor: 5.691

Review 4.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

Review 5.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

6.  Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G.

Authors:  Christian M Felix; Marc H Levin; Alan S Verkman
Journal:  J Neuroinflammation       Date:  2016-10-20       Impact factor: 8.322

Review 7.  Neuromyelitis optica spectrum disorders: An update.

Authors:  Lekha Pandit
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

8.  Multisystem involvement in neuromyelitis optica.

Authors:  Megan M Langille; Jay Desai
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

Review 9.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Authors:  Corinna Trebst; Sven Jarius; Achim Berthele; Friedemann Paul; Sven Schippling; Brigitte Wildemann; Nadja Borisow; Ingo Kleiter; Orhan Aktas; Tania Kümpfel
Journal:  J Neurol       Date:  2013-11-23       Impact factor: 4.849

Review 10.  Experimental models of neuromyelitis optica.

Authors:  Monika Bradl; Hans Lassmann
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.